Search

Your search keyword '"van Dijk, Anneke D."' showing total 18 results
Start Over Author "van Dijk, Anneke D."
18 results on '"van Dijk, Anneke D."'

1. Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial

Author

van Dijk, Anneke D., primary, Hoff, Fieke W., additional, Qiu, Yihua, additional, Hubner, Stefan E., additional, Go, Robin L., additional, Ruvolo, Vivian R., additional, Leonti, Amanda R., additional, Gerbing, Robert B., additional, Gamis, Alan S., additional, Aplenc, Richard, additional, Kolb, Edward A., additional, Alonzo, Todd A., additional, Meshinchi, Soheil, additional, de Bont, Eveline S. J. M., additional, Horton, Terzah M., additional, and Kornblau, Steven M., additional

Published
2024
Full Text
View/download PDF

4. Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study

Author

Hoff, Fieke W., van Dijk, Anneke D., Qiu, Yihua, Hu, Chenyue W., Ries, Rhonda E., Ligeralde, Andrew, Jenkins, Gaye N., Gerbing, Robert B., Gamis, Alan S., Aplenc, Richard, Kolb, E. Anders, Alonzo, Todd A., Meshinchi, Soheil, Qutub, Amina A., de Bont, Eveline S.J.M., Horton, Terzah M., and Kornblau, Steven M.

Abstract

Pediatric acute myeloid leukemia (AML) remains a fatal disease for at least 30% of patients, stressing the need for improved therapies and better risk stratification. As proteins are the unifying feature of (epi)genetic and environmental alterations, and are often targeted by novel chemotherapeutic agents, we studied the proteomic landscape of pediatric AML. Protein expression and activation levels were measured in 500 bulk leukemic patients’ samples and 30 control CD34+ cell samples, using reverse phase protein arrays with 296 strictly validated antibodies. The multistep MetaGalaxy analysis methodology was applied and identified nine protein expression signatures (PrSIG), based on strong recurrent protein expression patterns. PrSIG were associated with cytogenetics and mutational state, and with favorable or unfavorable prognosis. Analysis based on treatment (i.e., ADE vs. ADE plus bortezomib) identified three PrSIG that did better with ADE plus bortezomib than with ADE alone. When PrSIG were studied in the context of cytogenetic risk groups, PrSIG were independently prognostic after multivariate analysis, suggesting a potential value for proteomics in combination with current classification systems. Proteins with universally increased (n=7) or decreased (n=17) expression were observed across PrSIG. Certain proteins significantly differentially expressed from normal could be identified, forming a hypothetical platform for personalized medicine.

Published
2022

5. Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF‐κB subunit RelA

Author

van Dijk, Anneke D., primary, Hoff, Fieke W., additional, Qiu, Yihua, additional, Gerbing, Robert B., additional, Gamis, Alan S., additional, Aplenc, Richard, additional, Kolb, E. Anders, additional, Alonzo, Todd A., additional, Meshinchi, Soheil, additional, Jenkins, Gaye N., additional, de Bont, Eveline S. J. M., additional, Kornblau, Steven M., additional, and Horton, Terzah M., additional

Published
2021
Full Text
View/download PDF

6. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences

Author

van Dijk, Anneke D., primary, Griffen, Ti’ara L., additional, Qiu, Yihua H., additional, Hoff, Fieke W., additional, Toro, Endurance, additional, Ruiz, Kevin, additional, Ruvolo, Peter P., additional, Lillard, James W., additional, de Bont, Eveline S. J. M., additional, Burger, Jan A., additional, Wierda, William, additional, and Kornblau, Steven M., additional

Published
2021
Full Text
View/download PDF

11. Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

Author

van Dijk, Anneke D., primary, Ruvolo, Peter P., additional, Hoff, Fieke W, additional, Qiu, Yihua, additional, Gamis, Alan S, additional, Aplenc, Richard, additional, Kolb, Anders E., additional, Alonzo, Todd A., additional, Gerbing, Robert B., additional, de Bont, Eveline S., additional, Bruggeman, Sophia W.M., additional, Horton, Terzah M, additional, and Kornblau, Steven M., additional

Published
2019
Full Text
View/download PDF

12. Trimethylated H3K27, and Di- and Trimethylated H3K4 Proteomic Profiling Distinguishes Acute Lymphoid Leukemia (ALL) from Acute Myeloid Leukemia (AML) and Associates with Overall Survival and Tyrosine Kinase Inhibitor Sensitivity in Adult ALL

Author

van Dijk, Anneke D., primary, Hoff, Fieke W, additional, Qiu, Yihua, additional, Figueroa, Mary, additional, Chandra, Joya, additional, Jabbour, Elias, additional, de Bont, Eveline S., additional, and Kornblau, Steven M., additional

Published
2019
Full Text
View/download PDF

15. Prognostic Significance of FOXO3in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

Author

van Dijk, Anneke D., Ruvolo, Peter P., Hoff, Fieke W, Qiu, Yihua, Gamis, Alan S, Aplenc, Richard, Kolb, Anders E., Alonzo, Todd A., Gerbing, Robert B., de Bont, Eveline S., Bruggeman, Sophia W.M., Horton, Terzah M, and Kornblau, Steven M.

Abstract

The proteasome degrades unneeded and damaged proteins. Tumor cells highly depend on increased protein production and their degradation suggesting that malignant cells with a high proliferation index will be more sensitive to proteasome inhibition. The addition of the proteasome inhibitor Bortezomib (Velcade, 'BTZ') to standard pediatric AML chemotherapy (cytarabine, daunorubicin and etoposide, 'ADE') depleted leukemia-initiating cells in a phase 2 clinical trial in pediatric AML (pedi-AML) patients. A randomized phase 3 clinical trial was then conducted by the Children's Oncology Group (COG) comparing ADE and ADE+BTZ treatment regimes in pedi-AML (AAML1031). To determine if there were specific protein expression profiles that correlated with response to BTZ-containing chemotherapy, we analyzed key components of the proteome of pedi-AML that participated in the trial using reverse phase protein arrays (RPPA).

Published
2019
Full Text
View/download PDF

16. Proteoforms in Acute Leukemia : Evaluation of Age- and Disease-Specific Proteoform Patterns

Author

Hoff, Fieke W. W, van Dijk, Anneke D. Dirkje, and Kornblau, Steven M.

Subjects
Science / Life Sciences / Biochemistry
Abstract

Acute leukemia are a heterogeneous group of malignant diseases of the bone marrow that occur at all ages. Acute lymphoid leukemia (ALL) accounts for about 80% of all pediatric leukemia patients, whereas acute myeloid leukemia (AML) is more common in adults compared to pediatric patients. Despite similar patterns in the pathogenesis of acute leukemia in children and adults, clinical outcome in response to therapy differs substantially. Studying proteoforms in acute leukemia in children and adults, might identify similarities and differences in crucial signaling pathways that play a key role in the development or progression of the disease. In this chapter we will discuss how the study of proteoforms in acute leukemia could potentially contribute to a better understanding of the leukemogenesis, can help to identify effective targets for specific targeted treatment approaches in different subgroups of age and disease, and could aid the development of reliable biomarkers for prognostic stratification.

Published
2020

17. Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study.

Author

Hoff FW, Van Dijk AD, Qiu Y, Hu CW, Ries RE, Ligeralde A, Jenkins GN, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Qutub AA, De Bont ESJM, Horton TM, and Kornblau SM

Subjects
Bortezomib, Child, Humans, Prognosis, Protein Array Analysis, Proteins, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute metabolism, Proteomics
Abstract

Pediatric acute myeloid leukemia (AML) remains a fatal disease for at least 30% of patients, stressing the need for improved therapies and better risk stratification. As proteins are the unifying feature of (epi)genetic and environmental alterations, and are often targeted by novel chemotherapeutic agents, we studied the proteomic landscape of pediatric AML. Protein expression and activation levels were measured in 500 bulk leukemic patients' samples and 30 control CD34+ cell samples, using reverse phase protein arrays with 296 strictly validated antibodies. The multistep MetaGalaxy analysis methodology was applied and identified nine protein expression signatures (PrSIG), based on strong recurrent protein expression patterns. PrSIG were associated with cytogenetics and mutational state, and with favorable or unfavorable prognosis. Analysis based on treatment (i.e., ADE vs. ADE plus bortezomib) identified three PrSIG that did better with ADE plus bortezomib than with ADE alone. When PrSIG were studied in the context of cytogenetic risk groups, PrSIG were independently prognostic after multivariate analysis, suggesting a potential value for proteomics in combination with current classification systems. Proteins with universally increased (n=7) or decreased (n=17) expression were observed across PrSIG. Certain proteins significantly differentially expressed from normal could be identified, forming a hypothetical platform for personalized medicine.

Published
2022
Full Text
View/download PDF

18. Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA.

Author

van Dijk AD, Hoff FW, Qiu Y, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins GN, de Bont ESJM, Kornblau SM, and Horton TM

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bortezomib pharmacology, Bortezomib therapeutic use, Child, Cytarabine adverse effects, Humans, Neoplasm Recurrence, Local chemically induced, Neoplasm Recurrence, Local drug therapy, Phosphorylation, Transcription Factor RelA therapeutic use, Leukemia, Myeloid, Acute drug therapy, NF-kappa B
Abstract

Purpose: The addition of the proteasome inhibitor (PI) bortezomib to standard chemotherapy (ADE: cytarabine [Ara-C], daunorubicin, and etoposide) did not improve overall outcome of pediatric AML patients in the Children's Oncology Group AAML1031 phase 3 randomized clinical trial (AAML1031) . Bortezomib prevents protein degradation, including RelA via the intracellular NF-kB pathway. In this study, we hypothesized that subgroups of pediatric AML patients benefitting from standard therapy plus bortezomib (ADEB) could be identified based on pre-treatment RelA expression and phosphorylation status., Experimental Design: RelA-total and phosphorylation at serine 536 (RelA-pSer 536 ) were measured in 483 patient samples using reverse phase protein array technology., Results: In ADEB-treated patients, low-RelA-pSer 536 was favorably prognostic when compared to high-RelA-pSer 536 (3-yr overall survival (OS): 81% vs. 68%, p = 0.032; relapse risk (RR): 30% vs. 49%, p = 0.004). Among low-RelA-pSer 536 patients, RR significantly decreased with ADEB compared to ADE (RR: 30% vs. 44%, p = 0.035). Correlation between RelA-pSer 536 and 295 other assayed proteins identified a strong correlation with HSF1-pSer 326 , another protein previously identified as modifying ADEB response. The combination of low-RelA-pSer 536 and low-HSF1-pSer 326 was a significant predictor of ADEB response (3-yr OS: 86% vs. 67%, p = 0.013)., Conclusion and Clinical Relevance: Bortezomib may improve clinical outcome in a subgroup of AML patients identified by low-RelA-pSer 536 and low-HSF1-pSer 326 ., (© 2021 Wiley-VCH GmbH.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results